A detailed history of Brooks, Moore & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Brooks, Moore & Associates, Inc. holds 28,696 shares of ABBV stock, worth $4.82 Million. This represents 3.36% of its overall portfolio holdings.

Number of Shares
28,696
Previous 28,781 0.3%
Holding current value
$4.82 Million
Previous $4.46 Million 17.15%
% of portfolio
3.36%
Previous 3.11%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $13,584 - $15,478
-85 Reduced 0.3%
28,696 $5.23 Million
Q4 2023

Feb 15, 2024

SELL
$137.6 - $154.97 $27,520 - $30,994
-200 Reduced 0.69%
28,781 $4.46 Million
Q3 2023

Nov 15, 2023

SELL
$133.59 - $154.65 $180,212 - $208,622
-1,349 Reduced 4.45%
28,981 $4.32 Million
Q2 2023

Aug 15, 2023

SELL
$132.51 - $164.9 $64,664 - $80,471
-488 Reduced 1.58%
30,330 $4.09 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $84,596 - $97,425
585 Added 1.93%
30,818 $4.91 Million
Q4 2022

Feb 03, 2023

SELL
$138.31 - $165.87 $928,475 - $1.11 Million
-6,713 Reduced 18.17%
30,233 $4.89 Million
Q3 2022

Nov 17, 2022

BUY
$134.21 - $153.93 $119,715 - $137,305
892 Added 2.47%
36,946 $4.96 Million
Q2 2022

Aug 04, 2022

SELL
$137.62 - $174.96 $211,109 - $268,388
-1,534 Reduced 4.08%
36,054 $5.52 Million
Q1 2022

May 03, 2022

SELL
$131.98 - $163.75 $369,544 - $458,500
-2,800 Reduced 6.93%
37,588 $6.09 Million
Q4 2021

Feb 04, 2022

BUY
$107.43 - $135.93 $113,875 - $144,085
1,060 Added 2.7%
40,388 $5.47 Million
Q3 2021

Nov 08, 2021

SELL
$106.4 - $120.78 $494,228 - $561,023
-4,645 Reduced 10.56%
39,328 $4.24 Million
Q2 2021

Jul 21, 2021

SELL
$105.21 - $117.21 $39,453 - $43,953
-375 Reduced 0.85%
43,973 $4.95 Million
Q1 2021

May 04, 2021

BUY
$102.3 - $112.62 $242,962 - $267,472
2,375 Added 5.66%
44,348 $4.8 Million
Q4 2020

Feb 08, 2021

BUY
$80.49 - $108.67 $166,292 - $224,512
2,066 Added 5.18%
41,973 $4.5 Million
Q3 2020

Nov 02, 2020

BUY
$85.91 - $100.83 $577,229 - $677,476
6,719 Added 20.25%
39,907 $3.5 Million
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $173,960 - $232,784
2,371 Added 7.69%
33,188 $3.26 Million
Q1 2020

Apr 22, 2020

BUY
$64.5 - $97.79 $136,095 - $206,336
2,110 Added 7.35%
30,817 $2.35 Million
Q4 2019

Jan 30, 2020

BUY
$72.13 - $90.25 $72 - $90
1 Added 0.0%
28,707 $2.54 Million
Q3 2019

Oct 25, 2019

BUY
$62.98 - $75.72 $499,053 - $600,005
7,924 Added 38.13%
28,706 $2.17 Million
Q2 2019

Aug 09, 2019

BUY
$65.7 - $83.98 $208,597 - $266,636
3,175 Added 18.03%
20,782 $1.51 Million
Q1 2019

Apr 24, 2019

BUY
$77.14 - $90.79 $92,568 - $108,948
1,200 Added 7.31%
17,607 $1.42 Million
Q4 2018

Feb 06, 2019

BUY
$77.85 - $96.01 $1.28 Million - $1.58 Million
16,407 New
16,407 $1.51 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Brooks, Moore & Associates, Inc. Portfolio

Follow Brooks, Moore & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brooks, Moore & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brooks, Moore & Associates, Inc. with notifications on news.